Latest News | Glenmark Gets DCGI Nod for Favipiravir for Treatment of COVID-19 Patients '
Get latest articles and stories on Latest News at LatestLY. Drug firm Glenmark Pharmaceuticals on Friday said it has received approval from the Indian drug regulator to launch oral antiviral drug favipiravir for treatment of mild to moderate COVID-19 patients in the country.
New Delhi, Jun 19 (PTI) Drug firm Glenmark Pharmaceuticals on Friday said it has received approval from the Indian drug regulator to launch oral antiviral drug favipiravir for treatment of mild to moderate COVID-19 patients in the country.
It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation, Glenmark Pharmaceuticals said in a statement.
Also Read | YouTube Introduces New Tools to Help Advertisers Make Video Ads More Shoppable.
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
"This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak," Glenmark said.
Also Read | Facebook Acquires Swedish Startup Mapillary to Take On Google Maps.
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)